Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has wrapped up its Phase 2 study of the glioblastoma treatment paxalisib. The company has received the final.
Zacks Investment Research lowered shares of Kazia Therapeutics (NASDAQ:KZIA – Get Rating) from a hold rating to a sell rating in a research note published on Tuesday morning, Zacks.com reports. According to Zacks, “Kazia Therapeutics Limited is an oncology-focused biotechnology company. It develops anti-cancer drugs as well as provides pharmaceutical research and development technology solutions. […]
Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) is set to have a busy few days at the American Association for Cancer Research (AACR) annual meeting in New.
Kazia Therapeutics Limited (NASDAQ:KZIA – Get Rating) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 1,400 shares, a growth of 55.6% from the January 31st total of 900 shares. Based on an average daily volume of 24,200 shares, the days-to-cover ratio is […]